Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 70Lymphoma 54Lymphoma, Large B-Cell, Diffuse 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Hodgkin Disease 26Sarcoma 25Lymphoma, Follicular 25Lymphoma, Non-Hodgkin 24Leukemia 19Burkitt Lymphoma 17Multiple Myeloma 16Endometrial Neoplasms 15Neuroblastoma 14Ovarian Neoplasms 12Carcinoma, Hepatocellular 12Lymphoma, Large-Cell, Immunoblastic 11Lymphoma, Mantle-Cell 10Liposarcoma 9Neoplasms 8Lymphoma, Large-Cell, Anaplastic 8Leiomyosarcoma 8Histiocytoma, Malignant Fibrous 8Urinary Bladder Neoplasms 7Lymphoma, B-Cell, Marginal Zone 7Hemangiosarcoma 7Fibrosarcoma 7Wilms Tumor 6Triple Negative Breast Neoplasms 6Sarcoma, Synovial 6Neurofibrosarcoma 6

Interventions

temsirolimus 1dehydroftorafur 1Vincristine 1Sirolimus 1Razoxane 1Platinum 1Liver Transplantation 1Irinotecan 1Fluorouracil 1Doxorubicin 1Dexrazoxane 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × PRETEXT I Hepatoblastoma × Doxorubicin × Clear all
NCT00980460 2026-05-04

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
236 enrolled 18 charts
Gastrointestinal

PRETEXT I Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡